ISSN: 2165-7831
Journal of Blood & Lymph
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Changing Therapeutic Landscape of Chronic Lymphocytic Leukemia

Priyanka Pathak*
Physician, Kimmel Cancer Center, Department of Medical Oncology, Thomas Jefferson University, PA, USA
Corresponding Author : Priyanka Pathak
Physician, Kimmel Cancer Center
Department of Medical Oncology
Thomas Jefferson University
111 S. 11th St, Philadelphia, PA 19107
Tel: 281-536-9472
Email: Priyanka.pathak@jefferson.edu
Received: May 01, 2015; Accepted: May 03, 2015; Published: May 15, 2015
Citation: Pathak P (2015) The Changing Therapeutic Landscape of Chronic Lymphocytic Leukemia. J Blood Lymph 5:e120.doi:10.4172/2165-7831.1000e120
Copyright: © 2015 Pathak P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Visit for more related articles at Journal of Blood & Lymph

Editorial
Chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of mature but functionally incompetent lymphocytes which are monoclonal in origin. The disease course is highly variable-- with some patients having long survival times and never requiring treatment and others who live only for a few years even with treatment.
In the past, the treatment of CLL consisted of chemoimmunotherapy, usually with FCR (fludarabine, cyclophosphamide and rituximab), PCR (pentostatin, cyclophosphamide, rituximab) or BR (bendamustine and rituximab). Not all patients with CLL will require treatment. Considering the adverse effects of traditional chemotherapy, only patients with disabling symptoms or cytopenias proven to be secondary to CLL (not autoimmune related) are usually treated. A high white cell count or disfiguring lymphadenopathy are not indications for treatment.
Recent developments in the understanding of the B cell receptor (BCR) and the B-cell receptor pathway signaling have changed the therapeutic landscape of CLL. Most promising of the small molecule inhibitors target the bruton tyrosine kinase (BTK), phosphoinositide 3 kinase (PI3K) and B cell CLL/lymphoma protein 2 (BCL-2) family proteins. Out of the novel agents, two of them have already been approved for the treatment of CLL.
Ibrutinib is a first-in-class oral, selective, irreversible inhibitor of BTK, a member of the Tec kinase family involved in the BCR signaling cascade [1]. The drug was approved by the Food and Drug Administration (FDA) on February, 2015 for the treatment of patients with CLL who received at least one prior therapy. The approval was based on an open label multi-center study conducted by Byrd et al. [2]. They demonstrated an overall response rate of 58.3% in 48 patients with CLL who were treated with 420 mg of ibrutinib daily. The patient population was heavily pretreated (median number of previous therapies was 4) and the responses were independent of high risk features including 17p deletion. Toxic effects were limited, and responses were often durable with prolonged therapy. This benefit was later confirmed in a randomized open label multi-center phase III trial of ibrutinib versus ofatumumab in 391 previously treated patients with CLL or small lymhocytic lymphoma (SLL) [3]. The ORR, OS and PFS were significantly higher in the ibrutinib arm. Treatment with Ibrutinib is associated with an initial lymphocytosis which does not signify disease progression but rather the migration of leukemic B cells from the lymph nodes, bone marrow and spleen into the blood.

Idelalisib is a potent, oral, selective inhibitor of PI3Kdelta and promotes apoptosis [4]. FDA granted accelerated approval to idelalisib in July 2014 for treatment of relapsed follicular lymphoma or CLL/SLL who have received at least 2 prior lines of therapy. This was based on a phase II open label; multi-center trial of 125 non-Hodgkin lymphoma patients [5] 25 patients had SLL. Again, the patient population was heavily pretreated. The ORR was 57% with majority of them being PRs and the median duration of response was 12.5 months. Toxicity was higher than with ibrutinib with febrile neutropenia, diarrhea, colitis and pneumonia being the most common serious adverse effects. Transient lymphocytosis due to migration of lymphocytes was also seen with idelalisib.

 

 

 

 

Another phase III randomized, double blind study of idelalisib with rituximab versus placebo with rituximab in patients with heavily pretreated relapsed/refractory CLL showed significantly improved ORRs (81% versus 13%; p<0.001) and the OS rates at 12 months were 92% versus 80% (p=0.02) [6]. The responses were independent of high risk features and toxicities were slightly higher in the idelalisib group. Considering the results of this study, a combination of idelalisib and rituximab was recently approved for relapsed CLL.

These drugs raise some important points. The efficacy and the relatively low adverse effect profile of these drugs will have an impact on in the upfront setting in the treatment of CLL. In some patients with indolent disease, these drugs may completely replace traditional chemotherapy. As the responses are independent of high risk features, current prognostic markers may need to be reexamined. Since complete remissions are less common with these targeted therapies, the implication is that this will be a long term treatment much like the TKIs for CML. The typical scenario is that of an elderly patient in his 70’s who needs therapy and will take an oral drug and manage his CLL for the rest of his life. This also raises issues about compliance as well as financial aspects of the therapy. We may also start seeing a trend to treat patients in earlier stages of their disease due to their ease of administration and low toxicity profile. Lastly, with more novel agents in development, prioritizing the different lines of therapy warrants a discussion as well.
References






 
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11299
  • [From(publication date):
    August-2015 - Jul 29, 2016]
  • Breakdown by view type
  • HTML page views : 7542
  • PDF downloads :3757
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version